Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMBRAVE: IntErnational Observational Study on Primary Chemoradiotherapy and iMage-based Adaptive BRAchytherapy for Vaginal cancEr

NCT06514235 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT06514235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06514235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMBRAVE: IntErnational Observational Study on Primary Chemoradiotherapy and iMage-based Adaptive BRAchytherapy for Vaginal cancEr
Lead sponsor
Erasmus Medical Center
Phase
Observational
Overall status
Recruiting
Start date
November 28, 2022
Completion date
November 30, 2033
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vaginal neoplasms